Inventiva (CHIX:IVAP) Cyclically Adjusted Revenue per Share: €0.26 (As of Dec. 2025)


CHIX:IVAP Inventiva SA CHIX:IVAP
53 GF Score
Price €3.06
GF Value €0.24
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Inventiva Cyclically Adjusted Revenue per Share?

Inventiva CHIX:IVAP 53 Cyclically Adjusted Revenue per Share is €0.26 as of Dec. 2025. GuruFocus rates CHIX:IVAP with a GF Score™ of 53/100 and a GF Value™ of €0.24 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Inventiva's adjusted revenue per share data for the fiscal year that ended in Dec. 2025 was €0.024. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.26 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Inventiva's average Cyclically Adjusted Revenue Growth Rate was -18.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Inventiva was -6.70% per year. The lowest was -6.70% per year. And the median was -6.70% per year.

As of today (2026-06-29), Inventiva's current stock price is € 3.06. Inventiva's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2025 was €0.26. Inventiva's Cyclically Adjusted PS Ratio of today is 11.77.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Inventiva was 23.00. The lowest was 4.57. And the median was 10.29.


Inventiva  (CHIX:IVAp) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Inventiva's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.06/0.26
=11.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Inventiva was 23.00. The lowest was 4.57. And the median was 10.29.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Inventiva Cyclically Adjusted Revenue per Share Related Terms


Inventiva Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Inventiva's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventiva Cyclically Adjusted Revenue per Share Chart

Inventiva Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.36 0.21 0.36 0.26

Inventiva Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.00 0.36 0.00 0.26

CHIX:IVAP vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Inventiva's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inventiva Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inventiva's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Inventiva's Cyclically Adjusted PS Ratio falls into.


CHIX:IVAP
53GF Score
Inventiva SA CHIX:IVAP
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inventiva Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Inventiva's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0.024/120.9000*120.9000
=0.024

Current CPI (Dec. 2025) = 120.9000.

Inventiva Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 0.600 100.650 0.721
201712 0.309 101.850 0.367
201812 0.156 103.470 0.182
201912 0.298 104.980 0.343
202012 0.011 104.960 0.013
202112 0.107 107.850 0.120
202212 0.294 114.160 0.311
202312 0.385 118.390 0.393
202412 0.154 119.950 0.155
202512 0.024 120.900 0.024

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.26 mean?
Inventiva (CHIX:IVAP) has a Cyclically Adjusted Revenue per Share of €0.26 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Inventiva and its competitors.
Is Inventiva's Cyclically Adjusted Revenue per Share too high?
Inventiva's current Cyclically Adjusted Revenue per Share is €0.26. Overall, Inventiva has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inventiva's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Inventiva's Cyclically Adjusted Revenue per Share of €0.26 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Inventiva and its competitors. Inventiva's current Cyclically Adjusted Revenue per Share is €0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inventiva stock overvalued right now?
Based on GuruFocus' analysis, Inventiva (CHIX:IVAP) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.24, compared to a current price of €3.06 — trading 1175% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.26. Inventiva's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Inventiva (CHIX:IVAP), the current Cyclically Adjusted Revenue per Share is €0.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inventiva (CHIX:IVAP) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of €3.06 is trading 1175% above its estimated GF Value™ of €0.24. GuruFocus considers Inventiva to be Significantly Overvalued.

Key valuation signals for CHIX:IVAP:

  • Cyclically Adjusted Revenue per Share: €0.26
  • GF Value™: €0.24 vs. price of €3.06 (1175% above fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the CHIX:IVAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
53GF Score

Get the complete analysis for CHIX:IVAP

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.06
Price
€0.24
GF Value